

# Bryn Williams-Jones

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/847681/publications.pdf>

Version: 2024-02-01

103  
papers

1,783  
citations

304743

22  
h-index

330143

37  
g-index

105  
all docs

105  
docs citations

105  
times ranked

1714  
citing authors

#	ARTICLE	IF	CITATIONS
1	Conceptualising Ethical Issues in the Conduct of Research: Results from a Critical and Systematic Literature Review. <i>Journal of Academic Ethics</i> , 2022, 20, 335-358.	2.2	8
2	Colombian Adolescents'™ Preferences for Independently Accessing Sexual and Reproductive Health Services: A Cross-Sectional and Bioethics Analysis. <i>Sexual and Reproductive Healthcare</i> , 2022, 32, 100698.	1.2	0
3	Bio-Ethics and One Health: A Case Study Approach to Building Reflexive Governance. <i>Frontiers in Public Health</i> , 2022, 10, 648593.	2.7	8
4	La personne 'g'œe 'Assist'œe technologiquement'œ: quels d'œfis 'œthiques'œ? <i>Canadian Journal of Bioethics</i> , 2022, 5, 171.	0.1	0
5	Making Decisions about Service Provision for Clients with Low Back Pain: Perspectives of Canadian Physiotherapy Professionals. <i>Physiotherapy Canada Physiotherapie Canada</i> , 2021, 73, 47-55.	0.6	0
6	Agency, Pleasure and Justice: A Public Health Ethics Perspective on the Use of PrEP by Gay and Other Homosexually-Active Men. <i>Social Aspects of HIV</i> , 2021, , 131-141.	0.1	0
7	'œLet'œs Test Crazy Ideas'œ-A Laboratory for Experimental Bioethics. <i>American Journal of Bioethics</i> , 2021, 21, 57-58.	0.9	0
8	'œFostering Autonomy'œfor Adolescents to Access Health Services: A Need for Clarifications. <i>Journal of Adolescent Health</i> , 2021, 68, 1038-1039.	2.5	1
9	Misconduct and Misbehavior Related to Authorship Disagreements in Collaborative Science. <i>Science and Engineering Ethics</i> , 2020, 26, 1967-1993.	2.9	41
10	Researchers'™ Perceptions of Ethical Authorship Distribution in Collaborative Research Teams. <i>Science and Engineering Ethics</i> , 2020, 26, 1995-2022.	2.9	27
11	Anticipatory governance and moral imagination: Methodological insights from a scenario-based public deliberation study. <i>Technological Forecasting and Social Change</i> , 2020, 151, 119800.	11.6	28
12	COVID-19 and Moral Imperialism in Multinational Clinical Research. <i>Archives of Medical Research</i> , 2020, 51, 572-573.	3.3	18
13	Mapping responsible conduct in the uncharted field of research-creation: A scoping review. <i>Accountability in Research</i> , 2019, 26, 311-346.	2.4	3
14	Informal PrEP: an emerging need for nomenclature. <i>Lancet Public Health</i> , The, 2019, 4, e83.	10.0	5
15	Towards an Integration of PrEP into a Safe Sex Ethics Framework for Men Who Have Sex with Men. <i>Public Health Ethics</i> , 2019, 12, 54-63.	1.0	9
16	Supporting ethics educators in Canadian occupational therapy and physical therapy programs: A national interprofessional knowledge exchange project. <i>Journal of Interprofessional Care</i> , 2018, 32, 452-462.	1.7	3
17	Operationalizing wait lists: Strategies and experiences in three hospital outpatient physiotherapy departments in Montreal. <i>Physiotherapy Theory and Practice</i> , 2018, 34, 872-881.	1.3	10
18	Conflicts of interest policies for authors, peer reviewers, and editors of bioethics journals. <i>AJOB Empirical Bioethics</i> , 2018, 9, 194-205.	1.6	6

#	ARTICLE	IF	CITATIONS
19	Conflicts of interest and the (in)dependence of experts advising government on immunization policies. <i>Vaccine</i> , 2018, 36, 7439-7444.	3.8	4
20	Validation d'un questionnaire auto-administré sur les valeurs en politique publique de santé. <i>Canadian Journal of Public Health</i> , 2018, 109, 891-899.	2.3	0
21	Launch of the <i>Canadian Journal of Bioethics</i> . <i>Canadian Journal of Bioethics</i> , 2018, 1, 1-3.	0.1	0
22	Protecting public health or commercial interests? The importance of transparency during immunization campaigns. <i>Ethics, Medicine and Public Health</i> , 2017, 3, 241-245.	0.9	3
23	Technologies of the self in public health: insights from public deliberations on cognitive and behavioural enhancement. <i>Critical Public Health</i> , 2017, 27, 373-383.	2.4	1
24	Biopolitical Barriers to a Potterian Bioethics: The (Potentially) Missed Opportunity of Epigenetics. <i>American Journal of Bioethics</i> , 2017, 17, 15-17.	0.9	6
25	Low back pain: An investigation of biases in outpatient Canadian physical therapy. <i>Physical Therapy</i> , 2017, 97, 985-997.	2.4	7
26	Ethics education in public health: where are we now and where are we going?. <i>International Journal of Ethics Education</i> , 2017, 2, 109-124.	0.9	8
27	Imagining Truly Open Access Bioethics: From Dreams to Reality. <i>American Journal of Bioethics</i> , 2017, 17, 19-20.	0.9	7
28	Ethical Challenges for Patient Access to Physical Therapy: Views of Staff Members from Three Publicly Funded Outpatient Physical Therapy Departments. <i>Narrative Inquiry in Bioethics</i> , 2017, 7, 157-169.	0.1	17
29	Low Back Pain: Current Patterns of Canadian Physiotherapy Service Delivery. <i>Physiotherapy Canada</i> <i>Physiotherapie Canada</i> , 2017, 69, 49-56.	0.6	7
30	Are Military and Medical Ethics Necessarily Incompatible? A Canadian Case Study. <i>Journal of Law, Medicine and Ethics</i> , 2016, 44, 639-651.	0.9	4
31	Sam's Final Story. <i>Narrative Inquiry in Bioethics</i> , 2016, 6, 92-94.	0.1	1
32	Narrative Symposium: Political Influence on Bioethical Deliberation. <i>Narrative Inquiry in Bioethics</i> , 2016, 6, 3-36.	0.1	0
33	Ethics teaching in rehabilitation: results of a pan-Canadian workshop with occupational and physical therapy educators. <i>Disability and Rehabilitation</i> , 2016, 38, 2244-2254.	1.8	13
34	Assessment of a multimedia-based prospective method to support public deliberations on health technology design: participant survey findings and qualitative insights. <i>BMC Health Services Research</i> , 2016, 16, 616.	2.2	9
35	Preparing for the arrival of "pink Viagra" strengthening Canadian direct-to-consumer information regulations. <i>Cmaj</i> , 2016, 188, 319-320.	2.0	8
36	Ethical Issues Raised by Private Practice Physiotherapy Are More Diverse than First Meets the Eye: Recommendations from a Literature Review. <i>Physiotherapy Canada</i> <i>Physiotherapie Canada</i> , 2015, 67, 124-132.	0.6	32

#	ARTICLE	IF	CITATIONS
37	Drug Familiarization and Therapeutic Misconception Via Direct-to-Consumer Information. <i>Journal of Bioethical Inquiry</i> , 2015, 12, 259-267.	1.5	21
38	Factors influencing prioritization, frequency and duration of physiotherapy services. <i>Physiotherapy</i> , 2015, 101, e811.	0.4	1
39	An in-depth analysis of ethics teaching in Canadian physiotherapy and occupational therapy programs. <i>Disability and Rehabilitation</i> , 2015, 37, 2305-2311.	1.8	14
40	Regulating Direct-to-Consumer Drug Information: A Case Study of Eli Lilly's Canadian 40over40 Erectile Dysfunction Campaign. <i>Healthcare Policy</i> , 2015, 10, 16-23.	0.6	5
41	Governing 'dual-use' research in Canada: A policy review. <i>Science and Public Policy</i> , 2014, 41, 76-93.	2.4	19
42	<i>What place for ethics?</i>An overview of ethics teaching in occupational therapy and physiotherapy programs in Canada. <i>Disability and Rehabilitation</i> , 2014, 36, 775-780.	1.8	38
43	Should we perform kidney transplants on foreign nationals?. <i>Journal of Medical Ethics</i> , 2014, 40, 821-826.	1.8	14
44	Examining the ethical and social issues of health technology design through the public appraisal of prospective scenarios: a study protocol describing a multimedia-based deliberative method. <i>Implementation Science</i> , 2014, 9, 81.	6.9	17
45	Epigenetics and the Environment in Bioethics. <i>Bioethics</i> , 2014, 28, 327-334.	1.4	40
46	How do business model and health technology design influence each other? Insights from a longitudinal case study of three academic spin-offs. <i>Research Policy</i> , 2014, 43, 1025-1038.	6.4	97
47	Global pharmacogenomics: Where is the research taking us?. <i>Global Public Health</i> , 2014, 9, 312-324.	2.0	11
48	Health Care Professionals and Bedbugs: An Ethical Analysis of a Resurgent Scourge. <i>HEC Forum</i> , 2013, 25, 245-255.	0.8	4
49	Building Business Relationships Through the Web: How Medical Technology Companies Enroll Stakeholders in Innovation Development and Uptake. <i>International Review of Social Research</i> , 2013, 3, 89-112.	0.3	0
50	Barriers to research on research ethics review and conflicts of interest. <i>IRB: Ethics &amp; Human Research</i> , 2013, 35, 14-9.	0.8	9
51	Accessibility and transparency of editor conflicts of interest policy instruments in medical journals. <i>Journal of Medical Ethics</i> , 2012, 38, 679-684.	1.8	21
52	Promoting Research on Research Integrity in Canada. <i>Accountability in Research</i> , 2012, 19, 47-52.	2.4	6
53	A six minute video clip to ponder the values fostered by health technology. <i>Australasian Medical Journal</i> , 2012, 5, 560-564.	0.1	0
54	Combat Hospitalâ€™s deployment of ethics and entertainment. <i>Cmaj</i> , 2012, 184, 680-681.	2.0	1

#	ARTICLE	IF	CITATIONS
55	Dupras and Williams-Jones Respond. American Journal of Public Health, 2012, 102, e12-e13.	2.7	0
56	The Expert and the Lay Public: Reflections on Influenza A (H1N1) and the Risk Society. American Journal of Public Health, 2012, 102, 591-595.	2.7	15
57	Managing Conflicts of Interest Should Begin with Dialogue and Education, Not Punitive Measures. Journal of Bioethical Inquiry, 2012, 9, 221-222.	1.5	0
58	Authorship and Responsibility in Health Sciences Research: A Review of Procedures for Fairly Allocating Authorship in Multi-Author Studies. Science and Engineering Ethics, 2012, 18, 199-212.	2.9	108
59	How do medical device manufacturers'™ websites frame the value of health innovation? An empirical ethics analysis of five Canadian innovations. Medicine, Health Care and Philosophy, 2012, 15, 61-77.	1.8	13
60	A six-minute video-clip to ponder the values fostered by health technology. Australasian Medical Journal, 2012, 5, 560-4.	0.1	0
61	Pharmacogenomic technologies: a necessary "luxury" for better global public health?. Globalization and Health, 2011, 7, 30.	4.9	11
62	The worlds and modalities of engagement of design participants: A qualitative case study of three medical innovations. Design Studies, 2011, 32, 313-332.	3.1	32
63	Beyond a Pejorative Understanding of Conflict of Interest. American Journal of Bioethics, 2011, 11, 1-2.	0.9	16
64	Ethical health technology assessment in Latin America: lessons from Canada and Argentina. Acta Bioethica, 2011, 17, 225-236.	0.3	7
65	Research Integrity/Misconduct Policies of Canadian Universities. Canadian Journal of Higher Education, 2011, 41, 1-17.	0.5	30
66	Facteurs influençant la régulation des essais cliniques au Mali. , 2011, 8, .	0.4	0
67	REPRODUCTIVE TOURISM IN ARGENTINA: CLINIC ACCREDITATION AND ITS IMPLICATIONS FOR CONSUMERS, HEALTH PROFESSIONALS AND POLICY MAKERS. Developing World Bioethics, 2010, 10, 59-69.	0.9	61
68	Assessment of the impact of market regulation in Mali on the price of essential medicines provided through the private sector. Health Policy, 2010, 97, 130-135.	3.0	18
69	Containing Global Antibiotic Resistance: Ethical Drug Promotion in the Developing World. , 2010, , 505-524.		10
70	Principles for Incorporating Farmers in the Ethical Assessment of Genetically Modified Crops. Ethics in Biology, Engineering & Medicine, 2010, 1, 83-99.	0.1	0
71	Supervisor's "Student Relations: Examining the Spectrum of Conflicts of Interest in Bioscience Laboratories. Accountability in Research, 2009, 16, 106-126.	2.4	12
72	Legalistic or Inspirational? Comparing University Conflict of Interest Policies. Higher Education Policy, 2009, 22, 433-459.	2.0	6

#	ARTICLE	IF	CITATIONS
73	Conflict of Interest Policies at Canadian Universities: Clarity and Content. <i>Journal of Academic Ethics</i> , 2008, 6, 79-90.	2.2	13
74	What leads to better health care innovation? Arguments for an integrated policy-oriented research agenda. <i>Journal of Health Services Research and Policy</i> , 2008, 13, 251-254.	1.7	54
75	Personalized Medicine, Bioethics and Social Responsibilities: Re-thinking the Pharmaceutical Industry to Remedy Inequities in Patient Care and International Health. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2008, 6, 108-120.	0.2	15
76	Mapping translational research in personalized therapeutics: from molecular markers to health policy. <i>Pharmacogenomics</i> , 2007, 8, 177-185.	1.3	39
77	Stem Cell Research Ethics: Consensus Statement on Emerging Issues. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2007, 29, 843-848.	0.7	19
78	Mapping the integration of social and ethical issues in health technology assessment. <i>International Journal of Technology Assessment in Health Care</i> , 2007, 23, 9-16.	0.5	94
79	The Global HLA Banking of Embryonic Stem Cells Requires Further Scientific Justification. <i>American Journal of Bioethics</i> , 2007, 7, 45-46.	0.9	11
80	Asymmetry in Scientific Method and Limits to Cross-Disciplinary Dialogue. <i>Journal of Investigative Medicine</i> , 2007, 55, 130-141.	1.6	6
81	Challenges for Corporate Ethics in Marketing Genetic Tests. <i>Journal of Business Ethics</i> , 2007, 77, 33-44.	6.0	11
82	Pharmacogenetics: the bioethical problem of DNA investment banking. <i>Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences</i> , 2006, 37, 550-565.	1.3	19
83	Global bioethics – myth or reality?. <i>BMC Medical Ethics</i> , 2006, 7, E10.	2.4	31
84	Shifting emphasis from pharmacogenomics to theragnostics. <i>Nature Biotechnology</i> , 2006, 24, 942-946.	17.5	121
85	Democracy unleashed – unpacking the tooth fairy in drug industry R&D. <i>Nature Biotechnology</i> , 2006, 24, 1324-1326.	17.5	8
86	Democratising Access to Genetic Services. <i>Familial Cancer</i> , 2006, 5, 117-121.	1.9	7
87	Could endogenous substrates of drug-metabolizing enzymes influence constitutive physiology and drug target responsiveness?. <i>Pharmacogenomics</i> , 2006, 7, 1199-1210.	1.3	16
88	Be ready against cancer, now™: direct-to-consumer advertising for genetic testing. <i>New Genetics and Society</i> , 2006, 25, 89-107.	1.2	39
89	A Candidate Pathway Strategy for Integration of Pharmacogenomic Components of Variability in Antipsychotic Treatment Outcomes: A Focus on Aripiprazole. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2005, 3, 305-317.	0.3	3
90	Knowledge commons or economic engine - what's a university for?. <i>Journal of Medical Ethics</i> , 2005, 31, 249-250.	1.8	15

#	ARTICLE	IF	CITATIONS
91	A University Wide Model for the Ethical Review of Human Subjects Research. <i>Research Ethics</i> , 2005, 1, 39-44.	1.7	8
92	Social Contract Theory and Just Decision Making: Lessons from Genetic Testing for the BRCA Mutations. <i>Kennedy Institute of Ethics Journal</i> , 2004, 14, 115-142.	0.5	18
93	Consent is not enough" putting incompetent patients first in clinical trials. <i>Lancet, The</i> , 2003, 361, 2096-2097.	13.7	21
94	Actor-Network Theory: a tool to support ethical analysis of commercial genetic testing. <i>New Genetics and Society</i> , 2003, 22, 271-296.	1.2	85
95	Rhetoric and Hype. <i>Molecular Diagnosis and Therapy</i> , 2003, 3, 375-383.	3.3	52
96	Where There's a Web, There's a Way: Commercial Genetic Testing and the Internet. <i>Public Health Genomics</i> , 2003, 6, 46-57.	1.0	58
97	Ethics and genetics: susceptibility testing in the workplace. <i>Journal of Business Ethics</i> , 2002, 35, 235-241.	6.0	26
98	History of a gene patent: tracing the development and application of commercial BRCA testing. <i>Health Law Journal</i> , 2002, 10, 123-46.	0.2	35
99	Private genetic testing in Canada: a summary. <i>Health Law Review</i> , 2001, 9, 10-3.	0.1	1
100	Re-framing the discussion: commercial genetic testing in Canada. <i>Health Law Journal</i> , 1999, 7, 49-67.	0.2	5
101	Améliorer la compréhension et la gestion des conflits d'intérêts des experts conseillant la prise de décisions en santé publique. <i>BioéthiqueOnline</i> , 0, 5, .	0.0	1
102	A Procedure for Managing Conflict of Interest When Forming Thesis Juries. <i>BioéthiqueOnline</i> , 0, 6, .	0.0	0
103	Éthique et ontologie. , 0, , 91-94.		0